The DOI matches its Crossref record.
The epithelial-mesenchymal tansition (EMT) and colorectal cancer progression
Open accessAbstract
During embryonic development, epithelial cells must escape the structural constraints imposed by tissue architecture and adopt a phenotype more amenable to cell movement, a process known as the epithelial-mesenchymal transition (EMT). The progression of carcinomas to invasive and metastatic disease may also involve localized occurrences of EMT. However, data that support the actual occurrence of EMT in specific carcinomas and the relevance of this process to the progression of these tumors had been scant. This review highlights recent studies that substantiate the importance of the EMT to colorectal carcinoma. Specifically, a novel model for studying the EMT of colorectal carcinoma has been used to gain insight into the nature of the EMT itself and to identify molecular events that contribute to disease progression. Although loss of E-cadherin function is a primal event for the EMT, the expression of specific integrins such as alpha(v)beta6 as a consequence of the EMT enables invasive cells to interact with interstitial matrices and to sustain activation of TGF-beta. Of note, alpha(v)beta6 expression in tumors is a marker of cells that have undergone an EMT and it is prognostic for tumors that will progress more rapidly to terminal disease. The EMT also induces autocrine signaling involving VEGF and Flt-1 that enable invasive cells to become 'self-sufficient' for survival. Thus, the EMT appears to be an integral component of colorectal cancer progression and its analysis can yield novel targets for prognosis and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
Chronic inflammation and cytokines in the tumor microenvironment
Landskron, G., De la Fuente, M., Thuwajit, P., Thuwajit, C., & Hermoso, M. A. (2014) · Journal of Immunology Research · doi:10.1155/2014/149185 · Cited by 1,765
TGF-β and epithelial-to-mesenchymal transitions
Zavadil, J., & Böttinger, E. P. (2005) · Oncogene · doi:10.1038/sj.onc.1208927 · Cited by 1,578
Molecular Definition of Breast Tumor Heterogeneity
Shipitsin, M., Campbell, L. L., Argani, P., Weremowicz, S., Bloushtain-Qimron, N., Yao, J., Nikolskaya, T., Serebryiskaya, T., Beroukhim, R., Hu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.013 · Cited by 1,353
Epithelial-Mesenchymal Transition in Cancer: A Historical Overview
Ribatti, D., Tamma, R., & Annese, T. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100773 · Cited by 1,001
Liang, W.-C., Fu, W.-M., Wong, C.-W., Wang, Y., Wang, W.-M., Hu, G.-X., Zhang, L., Xiao, L.-J., Wan, D. C.-C., Zhang, J.-F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4154 · Cited by 571
EMT and inflammation: inseparable actors of cancer progression
Suarez‐Carmona, M., Lesage, J., Cataldo, D., & Gilles, C. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12095 · Cited by 566
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer
Pardali, K., & Moustakas, A. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.06.004 · Cited by 526
Exploring the Role of RGD-Recognizing Integrins in Cancer
Nieberler, M., Reuning, U., Reichart, F., Notni, J., Wester, H.-J., Schwaiger, M., Weinmüller, M., Räder, A., Steiger, K., & Kessler, H. (2017) · Cancers · doi:10.3390/cancers9090116 · Cited by 429
DiMeo, T. A., Anderson, K., Phadke, P., Feng, C., Perou, C. M., Naber, S., & Kuperwasser, C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4135 · Cited by 414
Hypoxia-driven selection of the metastatic phenotype
Sullivan, R., & Graham, C. H. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9062-2 · Cited by 410
Roots and stems: stem cells in cancer
Polyak, K., & Hahn, W. C. (2006) · Nature Medicine · doi:10.1038/nm1379 · Cited by 378
Roepman, P., Schlicker, A., Tabernero, J., Majewski, I., Tian, S., Moreno, V., Snel, M. H., Chresta, C. M., Rosenberg, R., Nitsche, U., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28387 · Cited by 346
Redox mechanisms switch on hypoxia-dependent epithelial–mesenchymal transition in cancer cells
Cannito, S., Novo, E., Compagnone, A., Valfrè di Bonzo, L., Busletta, C., Zamara, E., Paternostro, C., Povero, D., Bandino, A., Bozzo, F., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn216 · Cited by 309
Xiong, H., Hong, J., Du, W., Lin, Y.-W., Ren, L.-L., Wang, Y.-C., Su, W.-Y., Wang, J.-L., Cui, Y., Wang, Z.-H., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.295964 · Cited by 307
Shioiri, M., Shida, T., Koda, K., Oda, K., Seike, K., Nishimura, M., Takano, S., & Miyazaki, M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603193 · Cited by 287
Epithelial-Mesenchymal Transition Events during Human Embryonic Stem Cell Differentiation
Eastham, A. M., Spencer, H., Soncin, F., Ritson, S., Merry, C. L. R., Stern, P. L., & Ward, C. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2253 · Cited by 280
Arndt, G. M., Dossey, L., Cullen, L. M., Lai, A., Druker, R., Eisbacher, M., Zhang, C., Tran, N., Fan, H., Retzlaff, K., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-374 · Cited by 260
Turley, E. A., Veiseh, M., Radisky, D. C., & Bissell, M. J. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1089 · Cited by 253
Kamarajan, P., Ateia, I., Shin, J. M., Fenno, J. C., Le, C., Zhan, L., Chang, A., Darveau, R., & Kapila, Y. L. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008881 · Cited by 134
CCN5, a Novel Transcriptional Repressor of the Transforming Growth Factor β Signaling Pathway
Sabbah, M., Prunier, C., Ferrand, N., Megalophonos, V., Lambein, K., De Wever, O., Nazaret, N., Lachuer, J., Dumont, S., & Redeuilh, G. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01316-10 · Cited by 89
TWIST1 Overexpression is Associated with Nodal Invasion and Male Sex in Primary Colorectal Cancer
Valdés-Mora, F., Gómez del Pulgar, T., Bandrés, E., Cejas, P., Ramírez de Molina, A., Pérez-Palacios, R., Gallego-Ortega, D., García-Cabezas, M. A., Casado, E., Larrauri, J., et al. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0166-x · Cited by 75
Li, J., Zhou, Z., Zhang, J., Wang, M., Luan, X., Zhao, M., Jiang, G., Wang, G., Li, S., Xiang, W., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03618-5 · Cited by 8
Metadata
- Authors
- Bates, R. C., & Mercurio, A.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2005-04
- Volume
- 4
- Issue
- 4
- Pages
- 371-376
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- OpenAlex
- W2079016331
- Cited by
- 298
- References
- 0
- FWCI
- 6.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.